|
1
|
Rees JR, Onwuegbusi BA, Save VE, Alderson
D and Fitzgerald RC: In vivo and in vitro evidence for transforming
growth factor-beta1-mediated epithelial to mesenchymal transition
in esophageal adenocarcinoma. Cancer Res. 66:9583–9590. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen D, Zhao M and Mundy GR: Bone
morphogenetic proteins. Growth Factors. 22:233–241. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang S, Du J, Wang Z, Yuan W, Qiao Y,
Zhang M, Zhang J, Gao S, Yin J, Sun B, et al: BMP-6 promotes
E-cadherin expression through repressing deltaEF1 in breast cancer
cells. BMC Cancer. 7:2112007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shepherd TG and Nachtigal MW:
Identification of a putative autocrine bone morphogenetic
protein-signaling pathway in human ovarian surface epithelium and
ovarian cancer cells. Endocrinology. 144:3306–3314. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song
W, Devereaux LM, Jin D, Sampath TK and Morton RA: Expression of
bone morphogenetic protein receptors type-IA, -IB and -II
correlates with tumor grade in human prostate cancer tissues.
Cancer Res. 60:2840–2844. 2000.PubMed/NCBI
|
|
6
|
Celeste AJ, Iannazzi JA, Taylor RC, Hewick
RM, Rosen V, Wang EA and Wozney JM: Identification of transforming
growth factor beta family members present in bone-inductive protein
purified from bovine bone. Proc Natl Acad Sci USA. 87:9843–9847.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ebisawa T, Tada K, Kitajima I, Tojo K,
Sampath TK, Kawabata M, Miyazono K and Imamura T: Characterization
of bone morphogenetic protein-6 signaling pathways in osteoblast
differentiation. J Cell Sci. 112:3519–3527. 1999.PubMed/NCBI
|
|
8
|
Park Y, Kim JW, Kim DS, Kim EB, Park SJ,
Park JY, Choi WS, Song JG, Seo HY, Oh SC, et al: The bone
morphogenesis protein-2 (BMP-2) is associated with progression to
metastatic disease in gastric cancer. Cancer Res Treat. 40:127–132.
2008. View Article : Google Scholar
|
|
9
|
Rothhammer T, Poser I, Soncin F, Bataille
F, Moser M and Bosserhoff AK: Bone morphogenic proteins are
overexpressed in malignant melanoma and promote cell invasion and
migration. Cancer Res. 65:448–456. 2005.PubMed/NCBI
|
|
10
|
Langenfeld EM, Calvano SE, Abou-Nukta F,
Lowry SF, Amenta P and Langenfeld J: The mature bone morphogenetic
protein-2 is aberrantly expressed in non-small cell lung carcinomas
and stimulates tumor growth of A549 cells. Carcinogenesis.
24:1445–1454. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ide H, Yoshida T, Matsumoto N, Aoki K,
Osada Y, Sugimura T and Terada M: Growth regulation of human
prostate cancer cells by bone morphogenetic protein-2. Cancer Res.
57:5022–5027. 1997.PubMed/NCBI
|
|
12
|
Thériault BL, Shepherd TG, Mujoomdar ML
and Nachtigal MW: BMP4 induces EMT and Rho GTPase activation in
human ovarian cancer cells. Carcinogenesis. 28:1153–1162. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Milano F, van Baal JW, Buttar NS, Rygiel
AM, de Kort F, DeMars CJ, Rosmolen WD, Bergman JJ, VAn Marle J,
Wang KK, et al: Bone morphogenetic protein 4 expressed in
esophagitis induces a columnar phenotype in esophageal squamous
cells. Gastroenterology. 132:2412–2421. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Na YR, Seok SH, Kim DJ, Han JH, Kim TH,
Jung H, Lee BH and Park JH: Bone morphogenetic protein 7 induces
mesenchymal-to-epithelial transition in melanoma cells, leading to
inhibition of metastasis. Cancer Sci. 100:2218–2225. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alarmo EL, Korhonen T, Kuukasjärvi T,
Huhtala H, Holli K and Kallioniemi A: Bone morphogenetic protein 7
expression associates with bone metastasis in breast carcinomas.
Ann Oncol. 19:308–314. 2008. View Article : Google Scholar
|
|
16
|
Lim M, Chuong CM and Roy-Burman P: PI3K,
Erk signaling in BMP7-induced epithelial-mesenchymal transition
(EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional
cultures. Horm Cancer. 2:298–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen X, Liao J, Lu Y, Duan X and Sun W:
Activation of the PI3K/Akt pathway mediates bone morphogenetic
protein 2-induced invasion of pancreatic cancer cells Panc-1.
Pathol Oncol Res. 17:257–261. 2011. View Article : Google Scholar
|
|
18
|
Augeri DJ, Langenfeld E, Castle M,
Gilleran JA and Langenfeld J: Inhibition of BMP and of TGFβ
receptors downregulates expression of XIAP and TAK1 leading to lung
cancer cell death. Mol Cancer. 15:272016. View Article : Google Scholar
|
|
19
|
Yuen HF, McCrudden CM, Grills C, Zhang SD,
Huang YH, Chan KK, Chan YP, Wong ML, Law S, Srivastava G, et al:
Combinatorial use of bone morphogenetic protein 6, noggin and SOST
significantly predicts cancer progression. Cancer Sci.
103:1145–1154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Megumi K, Ishigami S, Uchikado Y, Kita Y,
Okumura H, Matsumoto M, Uenosono Y, Arigami T, Kijima Y, Kitazono
M, et al: Clinicopathological significance of BMP7 expression in
esophageal squamous cell carcinoma. Ann Surg Oncol. 19:2066–2071.
2012. View Article : Google Scholar :
|
|
21
|
Hu M, Liu Q, Song P, Zhan X, Luo M, Liu C,
Yang D, Cai Y, Zhang F, Jiang F, et al: Abnormal expression of the
mitotic checkpoint protein BubR1 contributes to the
anti-microtubule drug resistance of esophageal squamous cell
carcinoma cells. Oncol Rep. 29:185–192. 2013.
|
|
22
|
Pickup MW, Hover LD, Guo Y, Gorska AE,
Chytil A, Novitskiy SV, Moses HL and Owens P: Deletion of the BMP
receptor BMPR1a impairs mammary tumor formation and metastasis.
Oncotarget. 6:22890–22904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Langenfeld E, Hong CC, Lanke G and
Langenfeld J: Bone morphogenetic protein type I receptor
antagonists decrease growth and induce cell death of lung cancer
cell lines. PLoS One. 8:e612562013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wahdan-Alaswad RS, Song K, Krebs TL, Shola
DT, Gomez JA, Matsuyama S and Danielpour D: Insulin-like growth
factor I suppresses bone morphogenetic protein signaling in
prostate cancer cells by activating mTOR signaling. Cancer Res.
70:9106–9117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim SM, Ye S, Rah SY, Park BH, Wang H, Kim
JR, Kim SH, Jang KY and Lee KB: RhBMP-2 activates hippo signaling
through RASSF1 in esophageal cancer cells. Sci Rep. 6:268212016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kokorina NA, Zakharkin SO, Krebsbach PH
and Nussenbaum B: Treatment effects of rhBMP-2 on invasiveness of
oral carcinoma cell lines. Laryngoscope. 121:1876–1880.
2011.PubMed/NCBI
|
|
27
|
Peng J, Yoshioka Y, Mandai M, Matsumura N,
Baba T, Yamaguchi K, Hamanishi J, Kharma B, Murakami R, Abiko K, et
al: The BMP signaling pathway leads to enhanced proliferation in
serous ovarian cancer-A potential therapeutic target. Mol Carcinog.
55:335–345. 2016. View
Article : Google Scholar
|
|
28
|
Chen JC, Yang ST, Lin CY, Hsu CJ, Tsai CH,
Su JL and Tang CH: BMP-7 enhances cell migration and αvβ3 integrin
expression via a c-Src-dependent pathway in human chondrosarcoma
cells. PLoS One. 9:e1126362014. View Article : Google Scholar
|
|
29
|
Yuen HF, Chan YP, Chan KK, Chu YY, Wong
ML, Law SY, Srivastava G, Wong YC, Wang X and Chan KW: Id-1 and
Id-2 are markers for metastasis and prognosis in oesophageal
squamous cell carcinoma. Br J Cancer. 97:1409–1415. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hao J, Lee R, Chang A, Fan J, Labib C,
Parsa C, Orlando R, Andresen B and Huang Y: DMH1, a small molecule
inhibitor of BMP type i receptors, suppresses growth and invasion
of lung cancer. PLoS One. 9:e907482014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Herrera B, van Dinther M, Ten Dijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian
cancer cell proliferation. Cancer Res. 69:9254–9262. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lavery K, Swain P, Falb D and
Alaoui-Ismaili MH: BMP-2/4 and BMP-6/7 differentially utilize cell
surface receptors to induce osteoblastic differentiation of human
bone marrow-derived mesenchymal stem cells. J Biol Chem.
283:20948–20958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung JW, Yoon SM, Kim S, Jeon YH, Yoon BH,
Yang SG, Kim MK, Choe S and Kuo MM: Bone morphogenetic protein-9 is
a potent growth inhibitor of hepatocellular carcinoma and reduces
the liver cancer stem cells population. Oncotarget. Sep
16–2016.Epub ahead of print. View Article : Google Scholar
|
|
34
|
Zhou Q, Heinke J, Vargas A, Winnik S,
Krauss T, Bode C, Patterson C and Moser M: ERK signaling is a
central regulator for BMP-4 dependent capillary sprouting.
Cardiovasc Res. 76:390–399. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang M, Ku WY, Zhou Z, Dellon ES, Falk
GW, Nakagawa H, Wang ML, Liu K, Wang J, Katzka DA, et al:
BMP-driven NRF2 activation in esophageal basal cell differentiation
and eosinophilic esophagitis. J Clin Invest. 125:1557–1568. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Sun H, Zhao F, Lu P, Ge C, Li H,
Hou H, Yan M, Chen T, Jiang G, et al: BMP4 administration induces
differentiation of CD133+ hepatic cancer stem cells,
blocking their contributions to hepatocellular carcinoma. Cancer
Res. 72:4276–4285. 2012. View Article : Google Scholar : PubMed/NCBI
|
